Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
This study has been completed.
Sponsor:
Merck KGaA
Collaborators:
Merck A.E., Greece
Merck OY, Finland
Merck B.V., Netherlands
Merck A.B., Sweden
Merck, S.A., Portugal
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01080027
First received: March 2, 2010
Last updated: October 6, 2011
Last verified: October 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |